The paper provides a systematic review on the cost-of-illness studies in an age-associated condition with high prevalence, benign prostatic hyperplasia (BPH), published in Medline between 2005 and 2015. Overall 11 studies were included, which were conducted in 8 countries. In the US, the annual direct medical costs per patient ranged from $255 to $5,729, while in Europe from €253 to €1,251. In 2008, in the UK total annual direct medical costs of BPH were £180.8 million at national level. In the US, overall costs of BPH management in the private sector were estimated at $3.9 billion annually, of which $500 million was attributable to productivity loss (year 1999). Due to demographic factors and possible surgical innovations in the field of urology, the costs of BPH are likely to increase in the future. Over the next decade the age of retirement is projected to rise, consequently, the indirect costs related to aging-associated conditions such as BPH are expected to soar. To promote the transparent and cost-effective management of BPH, development of rational clinical guidelines would be essential that may lead to significant improvement in quality of care as well as reduction in healthcare expenditure.
Average effective age of retirement versus the official age in 2012 in OECD countries (2012): http://www.oecd.org/els/emp/Summary_2012_values.xls. Accessed: 07.05.2015.
Bellinger, A.S. – Elliott, S.P. – Yang, L. – Wei, J.T. – Saigal, C.S. – Smith, A. – Wilt, T.J. – Strope, S.A. (2012): Changes in initial expenditures for benign prostatic hyperplasia evaluation in the Medicare population: a comparison to overall Medicare inflation. Journal of Urology 187(5): 1739–1746.
Boncz, I. – Vajda, R. – Agoston, I. – Endrei, D. – Sebestyen, A. (2014): Changes in the health status of the population of Central and Eastern European countries between 1990 and 2010. European Journal of Health Economics 15(1): 137–141.
Brodszky, V. – Balint, P. – Geher, P. – Hodinka, L. – Horvath, G. – Koo, E. – Pentek, M. – Polgar, A. – Sesztak, M. – Szanto, S. – Ujfalussy, I. – Gulacsi, L. (2009): Disease burden of psoriatic arthritis compared to rheumatoid arthritis, Hungarian experiment. Rheumatology International 30(2): 199–205.
Commission of the European Communities. Regions 2020 – demographic challenges for European regions (2008): ec.europa.eu/regional_policy/sources/docoffic/working/regions2020/pdf/ regions2020_demographic.pdf. Accessed: 07.05.2015.
Cozar, J.M. – Huerta, A. (2013): Care management of patients with benign prostatic hyperplasia in Spain [Manejo asistencial del paciente con hiperplasia benigna de próstata en España].. Actas Urológicas Españolas–English edition 37(1): 60–61.
DiSantostefano, R.L. - Biddle, A.K. – Lavelle, J.P. (2006): An evaluation of the economic costs and patient-related consequences of treatments for benign prostatic hyperplasia. BJU International 97(5):1007–1016.
Emberton, M. – Anson, K. (1999): Acute urinary retention in men: an age old problem. British Medical Journal 318(7188): 921–925.
Ersek, K. – Kovacs, T. – Wimo, A. – Karpati, K. – Brodszky, V. – Pentek, M. – Jonsson, L. – Gustavsson, A. – McDaid, D. – Kenigsberg, P.A. – Valtonen, H. – Gulacsi, L. (2010): Costs of dementia in Hungary. The Journal of Nutrition Health and Aging 14(8): 633–639.
Fourcade, R.O. – Lacoin, F. – Roupret, M. – Slama, A. – Le Fur, C. – Michel, E. – Sitbon, A. – Cotte, F.E. (2012): Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia. World Journal of Urology 30(3): 419–426.
Gulacsi, L. – Pentek, M. (2014a): HTA in Central and Eastern European countries; the 2001: a space odyssey and efficiency gain. European Journal of Health Economics 15(7):675–680.
Gulacsi, L. – Rencz, F. – Pentek, M. – Brodszky, V. – Lopert, R. – Hever, N.V. – Baji, P. (2014b): Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries. European Journal of Health Economics 15(1): 27–34.
Gulacsi, L. – Rotar, A.M. – Niewada, M. – Loblova, O. – Rencz, F. – Petrova, G. – Boncz, I. – Klazinga, N.S. (2014c): Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria. European Journal of Health Economics 15(1): 13–25.
Heredi, E. – Rencz, F. – Balogh, O. – Gulacsi, L. – Herszenyi, K. – Hollo, P. – Jokai, H. – Karpati, S. – Pentek, M. – Remenyik, E. – Szegedi, A. – Brodszky, V. (2014): Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary. European Journal of Health Economics 15(1): 111–119.
Hever, N.V. – Pentek, M. – Ballo, A. – Gulacsi, L. – Baji, P. – Brodszky, V. – Damasdi, M. – Bognar, Z. – Toth, G. – Buzogany, I. – Szanto, A. (2014): Health Related Quality of Life in Patients with Bladder Cancer: A Cross-Sectional Survey and Validation Study of the Hungarian Version of the Bladder Cancer Index. Pathology and Oncology Research.
Johansen, T.E. – Istad, J.A. (2007): Long-term cost analysis of treatment options for benign prostatic hyperplasia in Norway. Scandinavian journal of urology and nephrology 41(2): 124–131.
Kirby, R.S. – Kirby, M. – Fitzpatrick, J.M. (2010): Benign prostatic hyperplasia: counting the cost of its management. BJU International 105(7): 901–902.
Litwin, M.S. – Saigal, C.S. – Yano, E.M. – Avila, C. – Geschwind, S.A. – Hanley, J.M. – Joyce, G.F. – Madison, R. – Pace, J. – Polich, S.M. – Wang, M. (2005): Urologic diseases in America Project: analytical methods and principal findings. Journal of Urology 173(3): 933–937.
Moradi, M. – Rencz, F. – Brodszky, V. – Moradi, A. – Balogh, O. – Gulacsi, L. (2015): Health status and quality of life in patients with psoriasis: an Iranian cross-sectional survey. Archives of Iranian Medicine 18(3): 153–159.
Pentek, M. – Bereczki, D. – Gulacsi, L. – Mikudina, B. – Aranyi, Z. – Juhos, V. – Baji, P. – Brodszky V. (2013): Survey of adults living with epilepsy in Hungary: health-related quality of life and costs [Epilepsziával élő felnőttek felmérése Magyarországon: életminőség és költségek]. Ideggyógyászati Szemle 66(7-8): 251–261.
Pentek, M. – Horvath, C. – Boncz, I. – Falusi, Z. – Toth, E. – Sebestyen, A. – Majer, I. – Brodszky, V. – Gulacsi, L. (2008): Epidemiology of osteoporosis related fractures in Hungary from the nationwide health insurance database, 1999–2003. Osteoporos International 19(2): 243–249.
Rencz, F. (2012): Health economics analysis of benign prostatic hyperplasia [A jóindulatú prosztata– megnagyobbodás egészség–gazdaságtani elemzése].. Köz–Gazdaság 7(3): 135–151.
Rencz, F. – Brodszky, V. – Péntek, M. – Balogh, O. – Remenyik, É. – Szegedi, A. – Holló, P. – Kárpáti, S. – Jókai, H. – Herszényi, K. – Herédi, E. – Szántó, S. – Gulácsi, L. (2014a): Disease burden of psoriasis associated with psoriatic arthritis in Hungary[Arthritis psoriaticával társuló középsúlyos és súlyos psoriasis betegségterhe Magyarországon]. Orvosi Hetilap 155(48): 1913–1921.
Rencz, F. – Brodszky, V. – Pentek, M. – Bereczki, D. – Gulacsi, L. (2015a): Health state utilities for migraine based on attack frequency: a time trade-off study. Neurological Sciences 36(2): 197–202.
Rencz, F. – Brodszky, V. – Varga, P. – Gajdacsi, J. – Nyirady, P. – Gulacsi, L. (2014b): The economic burden of prostate cancer. A systematic literature overview of registry-based studies [A prosztata r¨¢k gazdas¨¢gi terhe nagy betegregiszterek alapjñ]. Orvosi Hetilap 155(13): 509–520.
Rencz, F. – Gulacsi, L. – Tamasi, B. – Karpati, S. – Pentek, M. – Baji, P. – Brodszky, V. (2015b): Health related quality of life and its determinants in pemphigus: a systematic review and meta- analysis. British Journal of Dermatology.
Rencz, F. – Hollo, P. – Karpati, S. – Pentek, M. – Remenyik, E. – Szegedi, A. – Balogh, O. – Heredi, E. – Herszenyi, K. – Jokai, H. – Brodszky, V. – Gulacsi, L. (2014c): Moderate to severe psoriasis patients’ subjective future expectations regarding health-related quality of life and longevity. Journal of the European Academy of Dermatology and Venereology.
Rosen, R. – Altwein, J. – Boyle, P. – Kirby, R.S. – Lukacs, B. – Meuleman, E. – O’Leary, M.P. – Puppo, P. – Robertson, C. – Giuliano, F. (2003): Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). European Urology 44(6): 637–649.
Saigal, C.S. – Joyce, G. (2005): Economic costs of benign prostatic hyperplasia in the private sector. Journal of Urology 173(4): 1309–1313.
Saigal, C.S. – Movassaghi, M. – Pace, J. – Joyce, G. (2007): Economic evaluation of treatment strategies for benign prostatic hyperplasia--is medical therapy more costly in the long run? Journal of Urology 177(4): 1463–1467. discussion 1467.
Schulz, M.W. – Chen, J. – Woo, H.H. – Keech, M. – Watson, M.E. – Davey, P.J. (2002): A comparison of techniques for eliciting patient preferences in patients with benign prostatic hyperplasia. Journal of Urology 168(1):155–159.
Shrestha, L.B. (2000): Population aging in developing countries. Health Affairs (Millwood) 19(3): 204–12.
Speakman, M. – Kirby, R. – Doyle, S. – Ioannou, C. (2014): Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) - focus on the UK. BJU International.
Strope, S.A. – Elliott, S.P. – Smith, A. – Wei, J.T. – Wilt, T.J. – Saigal, C.S. (2011): Urologist practice styles in the initial evaluation of elderly men with benign prostatic hyperplasia. Urology 77(3): 535–540.
Tamas, G. – Gulacsi, L. – Bereczki, D. – Baji, P. – Takats, A. – Brodszky, V. – Pentek, M. (2014): Quality of life and costs in Parkinson’s disease: a cross sectional study in Hungary. PLoS One 9(9): e107704.
Taub, D.A. – Wei, J.T. (2006): The economics of benign prostatic hyperplasia and lower urinary tract symptoms in the United States. Current Urology Reports 7(4): 272–281.
The 2012 Ageing Report. Economic and Budgetary Projections for the 27 EU Member States (2010–2060). http://ec.europa.eu/economy_finance/publications/european_economy/2012/pdf/ ee-2012-2_en.pdf. Accessed: 07.05.2015.
van Exel, N.J. – Koopmanschap, M.A. – McDonnell, J. – Chapple, C.R. – Berges, R. – Rutten, F.F. (2006): Medical consumption and costs during a one-year follow-up of patients with LUTS suggestive of BPH in six european countries: report of the TRIUMPH study. European Urology 49(1): 92–102.
Wei, J.T. – Calhoun, E. – Jacobsen, S.J. (2005): Urologic diseases in America project: benign prostatic hyperplasia. Journal of Urology 173(4): 1256–1261.